Abstract
For many years alkylating agents especially chlorambucil had been considered drugs of choice for first-line treatment of progressive and symptomatic CLL. Subsequently, treatment approaches have included purine nucleoside analogs, fludarabine or cladribine, and monoclonal antibodies (mAb). Moreover, safety and efficacy of bendamustine were investigated in an open-label, randomized, comparative trial. In March 2008 bendamustine was approved by the USA FDA for the treatment of CLL. Recently, several new agents have been explored and have shown promise in treating CLL.These treatments include new mAbs, agents targeting the antiapoptotic bcl-2 family of proteins, receptors involved in mediating survival signals from the microenvironment, antisense oligonucleotides and other agents. The most promising are new mAbs targeted CD20 molecule, lumiliximab, apolizumab, galiximab and anti-CD40 mAbs. Oblimersen, flavopiridol, thalidomide and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials.
Keywords: CLL, bendamustin, ofatumumab, GA-101, lumiliximab, galiximab, epratuzumab, flavopiridol, oblimersen, bryostatin 1
Current Cancer Therapy Reviews
Title: New Therapies for Patients with Chronic Lymphocytic Leukemia
Volume: 4 Issue: 4
Author(s): Tadeusz Robak and Pawel Robak
Affiliation:
Keywords: CLL, bendamustin, ofatumumab, GA-101, lumiliximab, galiximab, epratuzumab, flavopiridol, oblimersen, bryostatin 1
Abstract: For many years alkylating agents especially chlorambucil had been considered drugs of choice for first-line treatment of progressive and symptomatic CLL. Subsequently, treatment approaches have included purine nucleoside analogs, fludarabine or cladribine, and monoclonal antibodies (mAb). Moreover, safety and efficacy of bendamustine were investigated in an open-label, randomized, comparative trial. In March 2008 bendamustine was approved by the USA FDA for the treatment of CLL. Recently, several new agents have been explored and have shown promise in treating CLL.These treatments include new mAbs, agents targeting the antiapoptotic bcl-2 family of proteins, receptors involved in mediating survival signals from the microenvironment, antisense oligonucleotides and other agents. The most promising are new mAbs targeted CD20 molecule, lumiliximab, apolizumab, galiximab and anti-CD40 mAbs. Oblimersen, flavopiridol, thalidomide and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials.
Export Options
About this article
Cite this article as:
Robak Tadeusz and Robak Pawel, New Therapies for Patients with Chronic Lymphocytic Leukemia, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413380
DOI https://dx.doi.org/10.2174/157339408786413380 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology Computational Studies of Competitive Inhibitors of Nitric Oxide Synthase (NOS) Enzymes: Towards the Development of Powerful and Isoform-Selective Inhibitors
Current Medicinal Chemistry Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Prostaglandins Pathway as a Possible Biological Link Between Cancer and Major Depression
Current Angiogenesis (Discontinued) Carotid Artery Stenting for the Prevention of Thromboembolic Stroke
Vascular Disease Prevention (Discontinued) Iridoids Analysis by Different Analytical Techniques and its Role as Pharmacologic Agents: A Review
Current Bioactive Compounds Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Peptides in Oral Diseases
Current Pharmaceutical Design Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry Perivascular Adipose Tissue, Inflammation and Vascular Dysfunction in Obesity
Current Vascular Pharmacology Prodrug Design Targeting Intestinal PepT1 for Improved Oral Absorption: Design and Performance
Current Drug Metabolism Exercise as Treatment for Neuropathy in the Setting of Diabetes and Prediabetic Metabolic Syndrome: A Review of Animal Models and Human Trials
Current Diabetes Reviews Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia
Current Signal Transduction Therapy Surgical Treatment of Pulmonary Embolism and Chronic Thromboembolic Pulmonary Hypertension
Current Pharmaceutical Design Tumor Angiogenesis and VEGFR-2: Mechanism, Pathways and Current Biological Therapeutic Interventions
Current Drug Metabolism Mechanisms of the Blunting of the Sympatho-Adrenal Response: A Theory
Current Diabetes Reviews Advanced Techniques for Imaging the Human Spinal Cord: Review of Literature
Current Medical Imaging Roles of Biogenic Amines in Intestinal Signaling
Current Protein & Peptide Science Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets